Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 9/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3864522 | 0.91 | ACHE (0.48) | ACHESLC6A4BCHEFAAHMEN1 | |
| SCHEMBL3877461 | 0.90 | MEN1 (0.41) | MEN1KMT2ACHRNB2CHRNA4 | |
| SCHEMBL3864586 | 0.81 | CHRNB2 (0.38) | CHRNB2CHRNA4 | |
| SCHEMBL3870281 | 0.75 | ACHE (0.40) | ACHEBCHEFAAHMARK4MEN1 | |
| SCHEMBL3863973 | 0.73 | ACHE (0.45) | ACHESLC6A4BCHECHRNB2CHRNA4 | |
| SCHEMBL3874786 | 0.73 | ACHE (0.40) | ACHESLC6A4 | |
| SCHEMBL3863046 | 0.73 | ACHE (0.45) | ACHEBCHE | |
| SCHEMBL3865156 | 0.72 | OPRK1 (0.45) | ACHEFAAH | |
| SCHEMBL3870406 | 0.72 | CYP3A4 (0.36) | ACHEBCHEFAAH | |
| SCHEMBL3874406 | 0.72 | L3MBTL1 (0.42) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149444-A1 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149444-A1 | Benzylamine analogues | HTR4, DRD4, SLC6A4 | ACHE 24/4885SLC6A4 3/4885BCHE 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.